Skip to main content
    R

    Royalty Pharma Plc (RPRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $68.53
    -0.79 (-1.13%)

    Market Cap: $39.85B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Royalty Pharma Plc (RPRX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    Royalty Pharma Plc reported revenue of $2.38B for the fiscal year ended Dec 31, 2025, up 5.1% from the year before. That year, net income was $1.32B with a net margin of 55.7%, operating cash flow was $2.49B and free cash flow was $2.49B. The quarter ended Sep 30, 2026 had revenue of $690.10M and net income of $266.64M.

    Revenue and Margins

    The operating margin was 65.6% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $1.88B, a compound annual rate of 2.7%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$2.38B+5.1%100.0%65.6%55.7%
    Dec 2024$2.26B-3.9%100.0%57.1%58.8%
    Dec 2023$2.35B+5.2%100.0%63.4%72.2%
    Dec 2022$2.24B-2.3%100.0%13.7%10.3%
    Dec 2021$2.29B+7.9%100.0%62.5%54.2%
    Dec 2020$2.12B+17.0%100.0%75.2%80.2%
    Dec 2019$1.81B+1.1%100.0%144.6%135.7%
    Dec 2018$1.79B+12.3%100.0%76.0%84.6%
    Dec 2017$1.60B-14.9%100.0%58.8%75.7%
    Dec 2016$1.88BN/A100.0%38.5%30.1%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income fell 0.8% from the year before. In the quarter ended Sep 2026, net income fell 39.4% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$2.38B$2.26B$2.35B$2.24B$2.29B$2.12B$1.81B$1.79B$1.60B$1.88B
    Cost of revenue$0$0$0$0$0$0$0$0$33.27M$0
    Gross profit$2.38B$2.26B$2.35B$2.24B$2.29B$2.12B$1.81B$1.79B$1.60B$1.88B
    Research and development$452.00M$2.00M$52.00M$177.11M$200.08M$26.29M$83.04M$392.61M$117.87M$91.02M
    Operating income$1.56B$1.29B$1.49B$307.06M$1.43B$1.60B$2.62B$1.36B$939.69M$722.87M
    Net income$1.32B$1.33B$1.70B$230.06M$1.24B$1.70B$2.46B$1.52B$1.21B$565.91M
    EBITDA$1.57B$1.48B$1.79B$354.33MN/A$1.81B$2.76B$1.81B$1.62B$1.07B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$690.10M$674.14M$630.58M$621.99M$609.29M$578.66M$568.25M$593.64M$564.69M$537.27M$567.98M$596.07M
    Gross profit$690.10M$674.14M$630.58M$621.99M$609.29M$578.66M$568.25M$593.64M$564.69M$537.27M$567.98M$596.07M
    Operating income$410.84M$133.12M$563.04M$388.38M$427.16M$209.80M$534.18M$361.51M$735.07M$269.63M-$73.77M$612.90M
    Net income$266.64M$81.49M$468.26M$355.91M$440.21M$92.64M$434.43M$334.35M$806.36M$194.38M-$4.27M$717.59M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $8.95B exceeded cash and equivalents by $8.33B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$19.62B$18.22B$16.38B$16.81B$17.52B$16.02B$12.45B$11.37B$11.37B$10.48B
    Current assets$1.53B$1.80B$1.27B$2.55B$2.88B$2.70B$832.07M$2.61B$2.95B$3.00B
    Cash and equivalents$618.70M$929.03M$477.01M$1.71B$1.54B$1.01B$246.20M$1.92B$1.38B$1.67B
    Total liabilities$9.91B$7.88B$6.30B$7.29B$7.27B$6.12B$6.31B$6.82B$6.90B$6.02B
    Short-term debt$380.00M$997.77M$0$997.51M$0$281.98M$281.98M$281.44M$280.93M$172.68M
    Long-term debt$8.57B$6.61B$6.14B$6.12B$7.10B$5.82B$5.96B$6.24BN/AN/A
    Shareholder equity$6.48B$6.95B$6.53B$5.63B$5.78B$4.82B$2.82B$4.49B$4.46B$4.45B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$19.46B$19.82B$19.82B$19.62B$19.35B$18.32B$17.61B$18.22B$18.04B$17.66B$16.13B$16.38B
    Total liabilities$9.67B$10.03B$9.88B$9.91B$9.73B$8.82B$7.82B$7.88B$7.78B$7.90B$6.27B$6.30B
    Cash and equivalents$513.66M$811.99M$586.39M$619.00M$938.94M$631.91M$1.09B$929.03M$950.05M$1.76B$843.00M$477.01M
    Shareholder equity$6.84B$6.83B$6.89B$6.48B$6.41B$6.35B$6.69B$6.95B$6.87B$6.48B$6.50B$6.53B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 100.0% of operating cash flow. Dividends and share repurchases together came to 85.5% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$2.49B$2.77B$2.99B$2.14B$2.02B$2.03B$1.67B$1.62B$1.42B-$15.58M
    Capital expenditures$0$0$2.12B$2.04B$523.00K$2.20B$1.72B$269.59M$2.29B$0
    Free cash flow$2.49B$2.77B$872.28M$102.83M$2.02B-$162.37M-$54.05M$1.35B-$872.39M-$15.58M
    Dividends paid$900.63M$863.90M$854.85M$950.70M$918.59M$1.12B$893.36M$1.08B$735.17MN/A
    Share repurchases$1.23B$229.65M$304.76M$0$0N/A$4.27M$0N/AN/A
    Investing cash flow-$1.61B-$2.68B-$2.07B-$1.03B-$1.87B-$2.76B-$2.15B$303.42M-$1.59BN/A
    Financing cash flow-$1.19B$361.14M-$2.15B-$944.86M$385.11M$1.49B-$1.19B-$1.38B-$123.25M$2.88M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$686.08M$728.46M$718.23M$827.15M$702.62M$363.98M$596.08M$742.52M$703.61M$658.21M$664.64M$772.63M
    Capital expendituresN/AN/A$0$0$1.11M$0$0$0$832.71M$746.63M$86.08M$1.00B
    Free cash flowN/AN/A$718.23M$827.15M$701.50M$363.98M$596.08M$742.52M-$129.10M-$88.42M$578.55M-$229.61M
    Last 12 quarters

    Frequently Asked Questions About RPRX

    What is Royalty Pharma Plc's annual revenue?

    Royalty Pharma Plc reported revenue of $2.38B for the fiscal year ended Dec 31, 2025.

    How fast is Royalty Pharma Plc's revenue growing?

    Revenue was up 5.1% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 2.1%.

    Is Royalty Pharma Plc profitable?

    Yes. Royalty Pharma Plc reported net income of $1.32B for the fiscal year ended Dec 31, 2025, with a net margin of 55.7%.

    How much free cash flow does RPRX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $2.49B minus capital expenditures of $0 produced free cash flow of $2.49B.

    How much debt does Royalty Pharma Plc have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $8.57B, short-term debt of $380.00M and cash and equivalents of $618.70M.